Patients with hyperthyroidism have reduced GH responses to pharmacological stimuli and reduced spontaneous nocturnal GH secretion. The stimulatory effect of arginine on GH secretion has been suggested to depend on a decrease in hypothalamic somatostatin tone. The aim of our study was to evaluate the effects of arginine on the GH-releasing hormone (GHRH)-stimulated GH secretion in patients with hyperthyroidism. Six hyperthyroid patients with recent diagnosis of Graves’ disease [mean age ± SEM, 39.2 ± 1.4 years; body mass index (BMI) 22 ± 0.4 kg/m2] and 6 healthy nonobese volunteers (4 males, 2 females; mean age ± SEM, 35 ± 3.5 years) underwent two experimental trials at no less than 7-day intervals: GHRH (100 µg, i.v.)-induced GH secretion was evaluated after 30 min i.v. infusion of saline (100 ml) or arginine (30 g) in 100 ml of saline. Hyperthyroid patients showed blunted GH peaks after GHRH (13.2 ± 2.9 µg/l) as compared with normal subjects (23.8 ± 3.9 µg/l, p < 0.05). GH peaks after GHRH were only slightly enhanced by arginine in hyperthyroid subjects (17.6 ± 2.9 µg/l), whereas, in normal subjects, the enhancement was clear cut (36.6 ± 4.4 µg/l; p < 0.05). GH values after arginine + GHRH were still lower in hyperthyroid patients with respect to normal subjects. Our data demonstrate that arginine enhances but does not normalize the GH response to GHRH in patients with hyperthyroidism when compared with normal subjects. We hypothesize that hyperthyroxinemia may decrease GH secretion, both increasing somatostatin tone and acting directly at the pituitary level.